ProfileGDS5678 / 1422399_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 46% 47% 47% 45% 46% 47% 47% 47% 45% 46% 54% 46% 48% 46% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1119846
GSM967853U87-EV human glioblastoma xenograft - Control 23.0926747
GSM967854U87-EV human glioblastoma xenograft - Control 33.0967447
GSM967855U87-EV human glioblastoma xenograft - Control 42.9898345
GSM967856U87-EV human glioblastoma xenograft - Control 53.0172146
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1939747
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1812547
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1147
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0440545
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0575546
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3121654
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0357446
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1413348
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0846146